: Patients with atrial fibrillation (AF) still experience a high mortality rate despite optimal antithrombotic treatment. We aimed to identify clinical phenotypes of patients to stratify mortality risk in AF. Cluster analysis was performed on 5171 AF patients from the nationwide START registry. The risk of all-cause mortality in each cluster was analyzed. We identified four clusters. Cluster 1 was composed of the youngest patients, with low comorbidities; Cluster 2 of patients with low cardiovascular risk factors and high prevalence of cancer; Cluster 3 of men with diabetes and coronary disease and peripheral artery disease; Cluster 4 included the oldest patients, mainly women, with previous cerebrovascular events. During 9857 person-years of observation, 386 deaths (3.92%/year) occurred. Mortality rates increased across clusters: 0.42%/year (cluster 1, reference group), 2.12%/year (cluster 2, adjusted hazard ratio (aHR) 3.306, 95% confidence interval (CI) 1.204-9.077, p = 0.020), 4.41%/year (cluster 3, aHR 6.702, 95%CI 2.433-18.461, p < 0.001), and 8.71%/year (cluster 4, aHR 8.927, 95%CI 3.238-24.605, p < 0.001). We identified four clusters of AF patients with progressive mortality risk. The use of clinical phenotypes may help identify patients at a higher risk of mortality.

Clinical phenotypes of atrial fibrillation and mortality risk-a cluster analysis from the nationwide italian START registry / Pastori, Daniele; Antonucci, Emilia; Milanese, Alberto; Menichelli, Danilo; Palareti, Gualtiero; Farcomeni, Alessio; Pignatelli, Pasquale; The Start Register Investigators, Null. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 12:5(2022). [10.3390/jpm12050785]

Clinical phenotypes of atrial fibrillation and mortality risk-a cluster analysis from the nationwide italian START registry

Pastori, Daniele
;
Milanese, Alberto;Menichelli, Danilo;Farcomeni, Alessio;Pignatelli, Pasquale;
2022

Abstract

: Patients with atrial fibrillation (AF) still experience a high mortality rate despite optimal antithrombotic treatment. We aimed to identify clinical phenotypes of patients to stratify mortality risk in AF. Cluster analysis was performed on 5171 AF patients from the nationwide START registry. The risk of all-cause mortality in each cluster was analyzed. We identified four clusters. Cluster 1 was composed of the youngest patients, with low comorbidities; Cluster 2 of patients with low cardiovascular risk factors and high prevalence of cancer; Cluster 3 of men with diabetes and coronary disease and peripheral artery disease; Cluster 4 included the oldest patients, mainly women, with previous cerebrovascular events. During 9857 person-years of observation, 386 deaths (3.92%/year) occurred. Mortality rates increased across clusters: 0.42%/year (cluster 1, reference group), 2.12%/year (cluster 2, adjusted hazard ratio (aHR) 3.306, 95% confidence interval (CI) 1.204-9.077, p = 0.020), 4.41%/year (cluster 3, aHR 6.702, 95%CI 2.433-18.461, p < 0.001), and 8.71%/year (cluster 4, aHR 8.927, 95%CI 3.238-24.605, p < 0.001). We identified four clusters of AF patients with progressive mortality risk. The use of clinical phenotypes may help identify patients at a higher risk of mortality.
2022
all-cause mortality; atrial fibrillation; phenotype; risk factors
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical phenotypes of atrial fibrillation and mortality risk-a cluster analysis from the nationwide italian START registry / Pastori, Daniele; Antonucci, Emilia; Milanese, Alberto; Menichelli, Danilo; Palareti, Gualtiero; Farcomeni, Alessio; Pignatelli, Pasquale; The Start Register Investigators, Null. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 12:5(2022). [10.3390/jpm12050785]
File allegati a questo prodotto
File Dimensione Formato  
Pastori_Clinical_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 555.31 kB
Formato Adobe PDF
555.31 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1639288
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact